» Articles » PMID: 30878395

MicroRNA-143-3p Promotes Human Cardiac Fibrosis Via Targeting Sprouty3 After Myocardial Infarction

Overview
Date 2019 Mar 18
PMID 30878395
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial infarction (MI) is one of the most catastrophic diseases threatening human health in the world. Because cardiomyocytes have a minuscule regenerative potential, the natural repair of infarct healing after MI shows fibrotic scar. MicroRNA-143-3p (miR-143-3p) plays a critical regulatory role in various pathophysiological processes in the heart. Sprouty3 (SPRY3) is predicted to be a potential fibrosis-associated target gene of miR-143-3p. The aim was to explore the role and mechanism of miR-143-3p in the infarct healing after MI in vivo and in vitro. Myocardial samples were obtained during autopsy from 12 human patients with or without MI. An increase in miR-143-3p mRNA levels was detected in the infarct zone of human MI samples. Moreover, silencing expression of miR-143-3p by antagomir-143-3p alleviated fibrotic scar in MI model of mice. To assess the mechanism by which miR-143-3p may function in fibrosis, human cardiac fibroblasts (HCFs) were transfected with miR-143-3p mimics and inhibitors. MiR-143-3p overexpression promoted HCFs proliferation, migration, transformation, and extracellular matrix (ECM) excessive accumulation. Additionally, miR-143-3p inhibitors reversed the fibrosis effect of HCFs treated with transforming growth β1 (TGFβ1) in vitro. Importantly, a luciferase reporter assay demonstrated that miR-143-3p could directly bind to the 3'-untranslational region (3'-UTR) of SPRY3 mRNA. Lastly, HCFs transfected with SPRY3 siRNA (si-SPRY3) enhanced the activation of the P38, ERK, and JNK pathways in the process of fibrosis. MiR-143-3p promoted fibrosis along with SPRY3 degradation and the activation of its downstream P38, ERK, and JNK pathways. Our results may contribute to improve the quality of life in MI patients by interfering with the role of miR-143-3p in MI area.

Citing Articles

Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers.

Moscoso I, Rodriguez-Manero M, Cebro-Marquez M, Vilar-Sanchez M, Serrano-Cruz V, Vidal-Abeijon I Int J Mol Sci. 2024; 25(22).

PMID: 39595980 PMC: 11593668. DOI: 10.3390/ijms252211910.


Epigenetic Regulation in Myocardial Fibroblasts and Its Impact on Cardiovascular Diseases.

Komal S, Gao Y, Wang Z, Yu Q, Wang P, Zhang L Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458994 PMC: 11510975. DOI: 10.3390/ph17101353.


Cardioprotective Action of the JNK Inhibitor Tryptanthrin Oxime in the Late Period after Myocardial Infarction.

Plotnikov M, Chernysheva G, Smolyakova V, Aliev O, Fomina T, Sandrikina L Bull Exp Biol Med. 2024; 177(5):643-647.

PMID: 39343845 DOI: 10.1007/s10517-024-06241-6.


Targeting MetaLnc9/miR-143/FSCN1 axis inhibits oxidative stress and myofibroblast transdifferentiation in oral submucous fibrosis.

Lu M, Hsieh P, Chao S, Fang C, Ohiro Y, Liao Y J Dent Sci. 2024; 19(3):1416-1425.

PMID: 39035266 PMC: 11259661. DOI: 10.1016/j.jds.2024.04.008.


Overexpression of zinc-finger protein 418 inhibits pathological cardiac remodelling after acute myocardial infarction.

Jiang H, Lai F, Wang X, Meng F, Zhu W, Huang S ESC Heart Fail. 2024; 11(5):2869-2880.

PMID: 38714309 PMC: 11424367. DOI: 10.1002/ehf2.14823.